Group items tagged

With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

The tool on apoptosis in oncology also assists in analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future.

The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

Government support with focus on water and environment fuels growth in the water and wastewater management market in India. The vast generation of wastewater in the country and related environmental degradation has long hinted at the need for having an efficient wastewater treatment mechanism in place. With gradual awareness and near-saturation levels of consumable water, Government is now focusing on this sector which is forecasted to exhibit steady growth over the next five years. While various policies are being drafted by the government to foster economic growth, an essential ingredient for progress of a country lies in mitigating water related woes and efficient water management.

Cheapgenericeddrug.com is one of the best online pharmacies. It deals in safe, effective and affordable generic ED medicines such as Generic Viagra, Generic Cialis and Generic Levitra.

Generic Viagra is a medication that contains the active ingredient sildenafil citrate and is used in the treatment of erectile dysfunction. Generic Viagra is available in different doses. Generic Viagra Known as a Sildenafil has been proven to be effective for the treatment of erectile dysfunction. Read More About Fildena Pills:- https://www.genericvilla.com/product/fildena/

Unmet needs in hematologic malignancies calls for companies focusing on PI3Ks and BTK inhibitors to offer better treatment options. Around USD 10 bn has already been invested in licensing and acquisition of PI3K and other kinase inhibitors since the last five years. Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell. Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential.

Analysis of leukemia business development enables tracking cutting edge companies, therapies and new technologies. Analysis of key areas of pharmaceutical R&D helps identify emerging leukemia products. The tool is designed in a way to assist in finding right partners, optimizing licensing deals and choosing projects that give the best competitive advantage.

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

Diabetic foot ulcers (DFUs) are a common complication of diabetes. With the increasing prevalence of diabetes across all markets the number of patients suffering from DFUs is also expected to rise. The global DFU therapeutics market is set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years. The first two topical antibacterial are also expected to be launched in the US and the five major EU markets. With the advent of these new product launches, the size of the DFU market is expected to grow substantially by 2017.

Emerging players with potentially strong product portfolio is expected to capture the global Xerosis treatment market. It is essential for the marketers to design effective counter-strategies to gain competitive advantage. A promising pipeline indicates mergers and acquisitions. Devising corrective measures for pipeline projects would also require an in-depth understanding of the Xerosis pipeline depth and focus of indication therapeutics.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.

The rapidly growing healthcare market in India continuously drives the demand for medical devices. Research on medical device market unveils that the booming Indian economy is witnessing a tremendous surge in the domestic healthcare scenario which, in turn, is leading to perpetual demand for high quality medical products. The demand for high-end, quality devices is especially driven by the private healthcare sector in its efforts to provide sophisticated treatment to patients.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company.

According to market forecasts, the global renal denervation market will witness significant growth over the next six years, jumping from USD 15.5 million in 2012 to USD 171.7 million by 2019, at a CAGR of 41%. This will mainly be attributable to the intervention's expected approval in major countries. It is stated that across 10 major markets in the major global economies (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India), only the European Union has approved the use of renal denervation.

Fildena 100 a well-known pill full of energy with S ildenafil Citrate as its active compound treats ED in men. The medicine serves as best technique to manage repeated penile failures. The formulation of this medicine guarantees to serve rock hard erection with toughness for longer hours.

Thanks for the info! What other medications can be used? And can ED be cured?

If you have the right diagnosis and go through the right treatment, erectile dysfunction can go away even without ED pills. Of course, there is a wide choice of such meds. For example, you can Buy viagra online https://www.canadadrugsdirect.com/products/viagra Though I recommend beginning by changing your daily routine, monitoring your nutrition and avoiding stress.